Ijeoma F. Uchegbu

Prof. Ijeoma F. Uchegbu

University College London, London, City of London, UK
orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2005 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
Christine DufèsChristine Dufès
Christine Dufès
IUIjeoma F. Uchegbu
Ijeoma F. Uchegbu
ASAndreas Schätzlein
Andreas Schätzlein

1 October 1998 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
IUIjeoma F. Uchegbu
Ijeoma F. Uchegbu
SVSuresh P. Vyas
Suresh P. Vyas

1 June 1995 in Advances in Colloid and Interface Science
Verified
Journal Article
Closed access
IUIjeoma F. Uchegbu
Ijeoma F. Uchegbu
AFAlexander T. Florence
Alexander T. Florence

1 October 2001 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
MBMaureen D. Brown
Maureen D. Brown
ASAndreas Schätzlein
Andreas Schätzlein
IUIjeoma F. Uchegbu
Ijeoma F. Uchegbu

1 July 2002 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
BZBernd H. Zinselmeyer
Bernd H. Zinselmeyer
SMSimon P. Mackay
Simon P. Mackay
ASAndreas Schätzlein
Andreas Schätzlein
IUIjeoma F. Uchegbu
Ijeoma F. Uchegbu

1 September 2019 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Open access
PDF file
ZWZian Wang
Zian Wang
GXGuojun Xiong
Guojun Xiong
WTWai Chun Tsang
Wai Chun Tsang
ASAndreas G Schätzlein
Andreas G Schätzlein
IUIjeoma F. Uchegbu
Ijeoma F. Uchegbu
The global prevalence of neurological disorders is rising and yet we are still unable to deliver most drug molecules, in therapeutic quantities, to the brain. The blood brain barrier, consists of a tight layer of endothelial cells surrounded by astrocyte foot processes and these anatomical features constitute a significant barrier to drug transport from the blood to the brain. One way to bypass the BBB and thus treat diseases of the brain is to use the nasal route of administration and deposit drugs at the olfactory region of the nares; from where they travel to the brain via mechanisms that are still not clearly understood; with travel across nerve fibres and travel via a perivascular pathway both being hypothesized. The nose to brain route has been demonstrated repeatedly in preclinical models, with both solution and particulate formulations. The nose to brain route has also been demonstrated in human studies with solution and particle formulations. The entry of device manufacturers into the arena will enable the benefits of this delivery route to become translated into approved products. The key factors which determine the efficacy of delivery via this route include: delivery to the olfactory area of the nares as opposed to the respiratory region, a longer retention time at the nasal mucosal surface, penetration enhancement of the active through the nasal epithelia and a reduction in drug metabolism in the nasal cavity. Indications where nose to brain products are likely to emerge first include: neurodegeneration, post-traumatic stress disorder, pain and glioblastoma. SIGNIFICANCE STATEMENT N/A